Citadel Advisors’s Mural Oncology MURA Stock Holding History

Citadel Advisors’s Portfolio MURA Stock Details MURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-83,800	Closed	-$173K	–	13588
2025 Q3	$173K	Buy	83,800 +19,600	+31%	+$42.1K	﹤0.01%	11405
2025 Q2	$159K	Buy	64,200 +60,200	+1,505%	+$142K	﹤0.01%	10910
2025 Q1	$5.04K	Sell	4,000 -3,600	-47%	-$13.1K	﹤0.01%	13845
2024 Q4	$24.5K	Buy	+7,600	New	+$26.8K	﹤0.01%	13041
2024 Q3	–	Sell	-4,200	Closed	-$13.2K	–	14876
2024 Q2	$13.2K	Buy	+4,200	New	+$15.5K	﹤0.01%	12952

Citadel Advisors's MURA Position: Q4 2025 in Review

Citadel Advisors sold out of Mural Oncology (MURA) in Q4 2025, closing a stake of 258,250 shares — an estimated $535K sold.

Citadel Advisors first reported a position in MURA in Q4 2023 and held it in 7 quarters. The position peaked at $1.47M in Q4 2023. 0 funds tracked by Wall St. Rank hold MURA as of Q4 2025.

Citadel Advisors reported no remaining Mural Oncology position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 258,250 Mural Oncology shares in Q4 2025, an estimated $535K.
Citadel Advisors first reported a position in Mural Oncology in Q4 2023 and held it in 7 quarters.
Citadel Advisors's Mural Oncology position peaked at $1.47M in Q4 2023.
0 funds tracked by Wall St. Rank held Mural Oncology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.